Neuropathic Pain

Alpha-lipoic acid crystals, magnified
Alpha-lipoic acid crystals, magnified
  1. What Neuropathic Pain Is
  2. Peripheral vs. Central Sensitization
  3. Common Causes and Conditions
  4. How Neuropathic Pain Feels: Symptoms and Descriptors
  5. DN4 Diagnostic Tool
  6. Diagnosing the Underlying Cause
  7. Gabapentinoids: Mechanism and Efficacy
  8. Serotonin-Norepinephrine Reuptake Inhibitor Treatment: Duloxetine
  9. Topical Treatments
  10. Alpha-Lipoic Acid and Evidence
  11. Other Treatment Options
  12. Complications
  13. Key Research Papers
  14. Connections

What Neuropathic Pain Is

Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system — the network of nerves responsible for sensing and transmitting information about pain, temperature, touch, and position. Unlike nociceptive pain (the normal protective pain signal from injured tissue — a stubbed toe, a burn), neuropathic pain arises from abnormal firing of damaged nerves themselves. The pain persists even when no tissue damage is occurring, and standard pain relievers often provide little relief. It affects an estimated 7–10% of the general population. Quality of life impacts are profound: sleep disruption, depression, anxiety, and reduced ability to work and socialize are common.

Back to Table of Contents

Peripheral vs. Central Sensitization

Understanding the difference helps explain why neuropathic pain is so hard to treat:

Back to Table of Contents

Common Causes and Conditions

Back to Table of Contents

How Neuropathic Pain Feels: Symptoms and Descriptors

Neuropathic pain has a distinctive character that distinguishes it from musculoskeletal pain. Patients describe:

Back to Table of Contents

DN4 Diagnostic Tool

The Douleur Neuropathique 4 (DN4) questionnaire is the most widely validated bedside tool for identifying neuropathic pain. It has a sensitivity of 82.9% and specificity of 89.9% for neuropathic pain vs. nociceptive pain. Score ≥4/10 indicates neuropathic pain.

Interview questions (patient reports):

  1. Does the pain have a burning quality?
  2. Is there a sensation of painful cold?
  3. Does the pain resemble electric shocks?
  4. Does pain feel like tingling?
  5. Does it feel like pins and needles?
  6. Does it feel like numbness?

Examination findings (clinician tests):

  1. Is the pain area hypoesthetic to touch?
  2. Is the pain area hypoesthetic to pinprick?
  3. Does brushing increase pain in the area?
  4. Does the pain area have autonomic signs?

Back to Table of Contents

Diagnosing the Underlying Cause

Diagnostic workup depends on clinical features and distribution. Standard evaluation includes:

Back to Table of Contents

Gabapentinoids: Mechanism and Efficacy

Gabapentin and pregabalin are first-line agents for many neuropathic pain types. Despite the name, they do not work at gamma-aminobutyric acid (GABA) receptors. Their actual mechanism: they bind to the α2δ (alpha-2-delta) subunit of voltage-gated calcium channels on presynaptic nerve terminals in the dorsal horn of the spinal cord. This reduces calcium influx and therefore decreases neurotransmitter release (including substance P, glutamate, and calcitonin gene-related peptide, CGRP) — dampening central sensitization.

Efficacy: In the 2015 Neuropathic Pain Special Interest Group (NeuPSIG) meta-analysis of 229 studies, the combined number needed to treat (NNT) for 50% pain relief was 7.7 for pregabalin and 7.2 for gabapentin — meaning about 7 to 8 people are treated for one to gain that much relief. The 2025 update (313 trials) put the NNT for the class as a whole (alpha-2-delta ligands) at 8.9. Response is variable and cannot be predicted.

Dosing: Gabapentin starts at 100–300 mg at bedtime, increases slowly to 900–3600 mg/day in divided doses. Pregabalin (faster onset, more linear absorption) starts at 75 mg twice daily, increases to 150–300 mg twice daily.

Side effects: sedation, dizziness, weight gain, peripheral edema, cognitive dulling — often dose-limiting. New pharmacovigilance concerns about misuse/dependence (particularly gabapentin) in the UK and some US states.

Comparing the first-line drugs: The UK OPTION-DM trial (2022; 130 people with painful diabetic neuropathy) gave amitriptyline, duloxetine and pregabalin in turn, each topped up with a second drug after 6 weeks if pain was still above 3 out of 10. All three treatment pathways gave similar relief: average pain fell from 6.6 to 3.3 out of 10 by week 16. Pain fell a further 1.0 point on average in people given the combination, against 0.2 points in those who stayed on one drug. Side effects followed each drug: more dizziness with pregabalin first, nausea with duloxetine first, and dry mouth with amitriptyline first.

Back to Table of Contents

Serotonin-Norepinephrine Reuptake Inhibitor Treatment: Duloxetine

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a first-line option for diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain.

Mechanism: Inhibit reuptake of both serotonin and norepinephrine in the descending pain modulation pathways from the periaqueductal gray and brainstem to the dorsal horn — enhancing the body's own pain-suppression circuitry. Norepinephrine is the key mediator (this explains why drugs that act on norepinephrine relieve pain better than selective serotonin reuptake inhibitors, SSRIs).

Duloxetine: U.S. Food and Drug Administration-approved for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain. Dose: 30 mg daily for 1 week then 60 mg daily. In the 2015 NeuPSIG meta-analysis the combined NNT for 50% pain relief was 6.4 for the SNRIs (mostly duloxetine trials); the 2025 update put the class at 7.4. Common side effects: nausea (usually transient), dry mouth, insomnia, sexual dysfunction, modest blood pressure (BP) increase.

Venlafaxine: Alternative serotonin-norepinephrine reuptake inhibitor (SNRI); evidence in painful polyneuropathy; stronger norepinephrine effect at higher doses (≥150 mg/day); requires cardiac monitoring at higher doses.

Back to Table of Contents

Topical Treatments

Topical agents allow higher local drug concentrations at the site of pain with minimal systemic absorption and side effects:

Back to Table of Contents

Alpha-Lipoic Acid and Evidence

Alpha-lipoic acid (ALA) is a naturally occurring antioxidant made by the body and found in small amounts in spinach, broccoli, and red meat. It plays a role in mitochondrial energy metabolism. For neuropathic pain, it acts as:

Clinical evidence: alpha-lipoic acid is the most evidence-supported natural treatment for diabetic peripheral neuropathy. The landmark SYDNEY trials (intravenous alpha-lipoic acid 600 mg/day × 3 weeks) showed significant reduction in total symptom score vs. placebo. In the SYDNEY 2 trial (2006; 181 people with diabetic nerve damage in Russia and Israel), oral alpha-lipoic acid taken once a day for 5 weeks at 600 mg, 1,200 mg or 1,800 mg lowered the total symptom score (stabbing pain, burning pain, pins and needles and numbness of the feet) by 51%, 48% and 52%, against 32% with placebo. At least half of the symptom score went away in 62%, 50% and 56% of people, against 26% on placebo. Nausea, vomiting and vertigo rose with the dose, and the authors concluded that 600 mg once daily gives the best balance of benefit and side effects. Alpha-lipoic acid is approved as a drug for diabetic neuropathy in Germany. In the US it is sold as a supplement (R-lipoic acid — the more bioavailable form — or racemic R+S).

Dose: the oral trial doses were 600–1,800 mg once daily; in SYDNEY 2, 600 mg once daily worked as well as 1,200 or 1,800 mg with fewer side effects. Side effects: gastrointestinal (GI) upset, rash; the research raises a concern for people with thiamine deficiency (it can worsen the deficiency).

Back to Table of Contents

Other Treatment Options

The 2025 NeuPSIG update: A review of 313 trials covering 48,789 adults made a strong recommendation for tricyclic antidepressants, alpha-2-delta ligands (gabapentin, pregabalin) and SNRIs as first-line treatments; a weak recommendation for capsaicin 8% patches, capsaicin cream and lidocaine 5% plasters as second line; and a weak recommendation for botulinum toxin A, repetitive transcranial magnetic stimulation and opioids as third line. The numbers needed to treat were 4.6 for tricyclic antidepressants, 8.9 for alpha-2-delta ligands, 7.4 for SNRIs, 5.9 for opioids, 2.7 for botulinum toxin A and 13.2 for capsaicin 8% patches. The authors describe treatment outcomes as modest, with uncertainty remaining for some treatments.

Back to Table of Contents

Complications

Neuropathic pain complications cascade: sleep deprivation from nocturnal pain leads to daytime fatigue and cognitive dysfunction; depression (40–65% prevalence in neuropathic pain); anxiety and catastrophizing (amplify pain perception); reduced physical activity leads to deconditioning and worsening pain; disability and unemployment; medication side effects (especially sedation with gabapentinoids and anticholinergic effects with tricyclic antidepressants); in diabetic neuropathy — loss of protective sensation leads to foot ulcers, infections, and amputations (described as largely preventable with foot care and glucose control).

Back to Table of Contents

Key Research Papers

  1. Treede RD et al., 2008 — Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. — PubMed PMID: 18003941
  2. Bouhassira D et al., 2004 — Development and validation of the Neuropathic Pain Symptom Inventory. Pain. — PubMed PMID: 15030944
  3. Bouhassira D et al., 2005 — Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. — PubMed PMID: 15733628
  4. Finnerup NB et al., 2015 — Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. — PubMed PMID: 25575710
  5. Raskin J et al., 2005 — A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. — PubMed PMID: 16266355
  6. Ziegler D et al., 1995 — Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. — PubMed PMID: 8786016
  7. Ziegler D et al., 2006 — Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. — PubMed PMID: 17065669
  8. Derry S et al., 2014 — Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. — PubMed PMID: 25058164
  9. Cruccu G et al., 2016 — EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. — PubMed PMID: 27511815
  10. Moore RA et al., 2011 — Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. — PubMed PMID: 21412914
  11. Derry S et al., 2019 — Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. — PubMed PMID: 30673120
  12. Soliman N et al., 2025 — Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol. — PubMed PMID: 40252663
  13. Tesfaye S et al., 2022 — Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet. — PubMed PMID: 36007534
  14. Petersen EA et al., 2021 — Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. — PubMed PMID: 33818600

PubMed Topic Searches

  1. PubMed: Neuropathic pain gabapentin pregabalin
  2. PubMed: Duloxetine neuropathic pain diabetic
  3. PubMed: Alpha lipoic acid diabetic neuropathy
  4. PubMed: Topical lidocaine postherpetic neuralgia
  5. PubMed: Small fiber neuropathy skin biopsy
  6. PubMed: Central sensitization chronic pain

Back to Table of Contents

Connections

Back to Table of Contents